Omidria 1-0.3% vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRL4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,882
Award facts
- Contract value 100% obligated
- $4,881.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,881.56 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of OMIDRIA 1-0.3% Vial 4ML. This firm fixed-price delivery order, issued on November 28, 2025, with an ultimate completion date of December 19, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a critical supplier within the federal pharmaceutical supply chain, with no identified subcontractors on this award.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499.999 billion with an ultimate completion date of December 31, 2036. The contract structure enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRL4?
SPE2DR26FCRL4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FCRL4 worth?
The government has obligated $4,882 on SPE2DR26FCRL4.
Is contract SPE2DR26FCRL4 an order under another contract?
Yes. SPE2DR26FCRL4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRL4 competed?
The extent of competition for SPE2DR26FCRL4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award